This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Puma Biotech (PBYI) closed the most recent trading day at $5.49, moving -0.63% from the previous trading session.
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
by Zacks Equity Research
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
PBYI vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
by Zacks Equity Research
Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
by Zacks Equity Research
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
by Zacks Equity Research
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.